Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response

Susanne Isfort,Dominik Wolf,Lino L Teichmann,Martina Crysandt,Andreas Burchert,Andreas Hochhaus,Susanne Saussele,Alexander Kiani,Joachim R Göthert,Thomas Illmer,Philippe Schafhausen,Mareille Warnken-Uhlich,Uta Wolber,Denise Kohn,Kirsi Manz,Markus Pfirrmann,Tim H Brümmendorf

doi:10.1182/blood-2021-151240

Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response

Susanne Isfort, Dominik Wolf + Show 15 more

Open Access

https://doi.org/10.1182/blood-2021-151240

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2021
Citations: 3

Affiliation: RWTH Aachen University, Innsbruck Medical University, University Hospital Bonn, Philipps University of Marburg, Jena University Hospital, University of Mannheim, Bayreuth Medical Center, University of Duisburg-Essen, Onkozentrum Dresden, University Medical Center Hamburg-Eppendorf, Ludwig-Maximilians-Universität München, Zimmer Biomet (Germany)

#Advisory Committees #Travel Reimbursement + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.